FIELD: organic chemistry, steroids, medicine, pharmacy. SUBSTANCE: invention describes novel neuroactive steroids of androstane and pregnane order of the formula (I) or their physiologically acceptable 3-esters where R means H or lower alkoxy-group; R1 means H, C1-10-alkyl, C2-10-alkenyl, C2-10-alkynyl, halogen-C1-10-alkyl, trihalogen-C1-10-alkyl, hydroxy-C2-10-alkynyl, alkoxy-C1-10- alkyl, optionally substituted phenylalkynyl, hydroxyalkynyldicarboxylic acid hemiester; R2 means H or keto-group; R3 means optionally substituted alkoxy-, alkynylhydroxy-, optionally substituted phenyl- alkynylhydroxy-group, -C(O)-CH2-Y-G, -C(O)-CH2-O-D, -C(O)-CH2-O-E, -C(O)-CH2-Z-G or C(O)- CH2-Y-Z-A where Y means O, S, SO or SO2; Z means C1-10-alkyl; G means pyridyl or optionally substituted phenyl; D means quinoline joined to carbon atom; E means optionally substituted phenyl; A means OH, carboxyl or sulfonate; R4 means H; R5 means H; R6 means H; R7 means H or OH; R8 means H; R9 means H; R10 means H under condition that: when R3 means C1-3-alkoxy-group and R means H then R1 differs from H; when R3 means C1-4-alkoxy-C1-4/ - -alkoxy-group then R1 differ from H or 1-propenyl; when R3 means -C(O)-CH2-Y-G and G means pyridyl joined to carbon atom then R1 differs from H or C1-10-alkyl; or when R3 means C(O)-CH2-Z-G then R1 differs from H. Compounds of the formula (I) are able to effect on brain excitability and relieve stress, insomnia, mood disorders caused by agents exhibiting activity with respect to GRC. EFFECT: improved method of treatment and prophylaxis, valuable medicinal properties. 39 cl, 10 tbl, 1 dwg, 49 ex
Title |
Year |
Author |
Number |
STEROID COMPOUNDS (VARIANTS), PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF PATIENTS WITH NERVOUS DISORDERS (VARIANTS) AND METHOD OF ANESTHESIA INDUCTION IN ANIMAL |
1995 |
- Boldzhehr Majkl B.
- Gi Kelvin U.
- Lehn Nensi K.
- Pehrdi Robert
- Takhir Khasan
- Jupehzehnaj Rehjvindra B.
|
RU2176248C2 |
NEW STEROID COMPOUNDS SHOWING HIGHER WATER SOLUBILITY AND METABOLISM RESISTANCE, AND METHODS FOR PREPARING THEM |
2007 |
- Behkstrem Torb'Ern
- Ragagnin Dzhinna
|
RU2458065C2 |
DERIVATIVES OF ANDROSTANE SUBSTITUTED AT 16-POSITION WITH QUATERNARY AMMONIUM GROUP, PHARMACEUTICAL COMPOSITION |
1993 |
- Zoltan Tuba
- Sil'Vester E.Vizi
- Ferents F.Foldes
- Shandor Makho
|
RU2124021C1 |
ANDROSTANES |
1995 |
- Dehvid L. Berliner
- Natan V. Adams
- Kliv L. Dzhennings-Vajt
|
RU2160740C2 |
METHOD OF SYNTHESIS OF DISUBSTITUTED 2,3-HYDROXYMETHYLCYCLOBUTANOL |
1993 |
- Dzhenek Sing
- Gregori S.Bissachi
- Richard Kh.Mjuller
|
RU2118312C1 |
OLIGOSACCHARIDE-CONTAINING 14-AMINOSTEROIDS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT, METHOD OF AMINO-GROUP INCORPORATION |
1994 |
- Dibajs Pol' Majkl
- Dzhonson Roland Norman
- Maf Rendi Stjuart
- L'Ju Song
- Portlok Dehvid Ehdvard
|
RU2153503C2 |
ANDROSTEN(ANE) (ONE) DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF, METHODS OF PREPARATION THEREOF, AND METHOD OF MEDICAL TREATMENT |
1994 |
- Behchelor Kennet Uil'Jam
- Fraj Stiven Vernon
|
RU2144037C1 |
METHOD OF TREATMENT OF PATIENTS WITH PROSTATE BENIGNITY HYPERPLASIA, PHARMACEUTICAL PREPARATION CONTAINING INHIBITOR OF 5-ALPHA-REDUCTASE |
1992 |
- Glenn Dzh.Gomlej
- Ehlizabet Stoner
|
RU2125879C1 |
16α-BROMO-3β-HYDROXY-5α-ANDROSTANE-17-ONE SEMIHYDRATE, METHOD FOR ITS PREPARING, PHARMACEUTICAL COMPOSITIONS, USING COMPOUNDS |
2000 |
- Alem Klarens Nataniehl
- Frinke Dzhejms Martin
- De Karval'O Luis Daniehl' Dos Ankhos
- Khehggi Vil'Jam
- Prendergast Patrik T.
- Riding Kristofer L.
- Tadikonda Krupakar Pol
- Vernon Rassehl' Nehjl
|
RU2295534C2 |
INHIBITORS OF TESTOSTERONE 5α-REDUCTASE, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITION OF TESTOSTERONE 5α-REDUCTASE ACTIVITY |
1993 |
- Fernand Labri
- Iv Meran
- Shankar M.Singkh
|
RU2141967C1 |